-
After the tumor, the pharmaceutical company has accelerated its layout in the field of autoimmunity
Time of Update: 2022-05-02
According to the agreement, Sino-US Huadong will obtain the licenses of Kiniksa's two global innovative products in the field of autoimmunity, Arcalyst and Mavrilimumab, in 24 Asia-Pacific countries and regions (excluding Japan), including China, South Korea, Australia, New Zealand and India, including development, registration and commercialization rights .
-
This local CAR-T cell therapy company, the overseas factory started operation!
Time of Update: 2022-05-02
According to public information, Keji Bio is a biopharmaceutical company with operations in China and the United States, mainly focusing on innovative CAR-T cell therapy for the treatment of hematological malignancies and solid tumors .
-
Yangzijiang Sodium Potassium Magnesium Sulfate Oral Solution and Levofloxacin Sodium Chloride Injection were approved for marketing
Time of Update: 2022-05-01
On March 3, NMPA's official website showed that Yangzijiang Pharmaceutical's sodium potassium magnesium sulfate oral solution and levofloxacin sodium chloride injection were approved for marketing, which are deemed to have passed the consistency evaluation .
-
This local pharmaceutical company's revenue exceeded 30 billion yuan, surpassing Roche, Merck and other businesses in China
Time of Update: 2022-05-01
Among them, more than 240 domestic pharmaceutical companies have released performance forecasts, and the world's major multinational pharmaceutical companies, including AstraZeneca, Roche, Merck, Sanofi, Novartis, Eli Lilly, etc.
-
1.3 billion oral hypoglycemic drugs!
Time of Update: 2022-05-01
On February 18, NMPA's official website showed that Tianjin Zhongxin Pharmaceutical's Gliclazide sustained-release tablets passed the consistency evaluation of generic drugs, making it the fifth company to pass the evaluation .
Sales of Gliclazide sustained-release tablets in Chinese public medical institutions (unit: ten thousand yuan) Source: Minet.
-
Regato Medical Mobile Head and Neck MRI System Approved for Market
Time of Update: 2022-05-01
The product consists of permanent magnet, gradient amplifier, gradient shim coil, RF amplifier, RF transmit coil, head coil (optional), head and neck combined coil (optional), spectrometer, temperature controller, digital shim unit, mobile It consists of a device, a shielding cover, a hospital bed, and an alarm unit for clinical MRI diagnosis of the head and neck .
-
The first pharmaceutical company on the Science and Technology Innovation Board held a performance briefing, and it has been listed for less than three months
Time of Update: 2022-05-01
On March 1, it was reported that two companies including Dizhe Medicine took the lead and opened the 2021 performance briefing on the Science and Technology Innovation Board . At present, the number
-
Qilu's QLS31906 for Class 1 biological drug injection was approved to enter the 100 billion market
Time of Update: 2022-05-01
Chemical sales of terminal anti-tumor drugs in Chinese public medical institutions (unit: ten thousand yuan) Source : Minet At present, Qilu Pharma has 24 Class 1 new drugs in the pipeline of clinical application and above, including 18 macromolecular biological drugs, involving monoclonal antibody, double antibody and ADC .
-
Yilian Biotech received US$70 million in Series B financing to accelerate ADC drug development
Time of Update: 2022-04-29
In recent years, domestic antibody-drug conjugate (ADC) drug research and development has been hot, and it has become a key direction for the layout of global innovative pharmaceutical companies.
-
[Live Preview] From exploration to landing - CAD detectors help the pharmaceutical industry to provide multi-faceted solutions
Time of Update: 2022-04-28
How to effectively solve various problems in the process of pharmaceutical R&D and production, and explore and practice the development path of biopharmaceutical compliance has become the concern and urgent problem of the whole industry .
-
The pharmaceutical company's innovative drug revenue growth rate is strong, up 53.8% year-on-year
Time of Update: 2022-04-22
According to the 2021 annual report released by Simcere Pharmaceuticals recently, during the reporting period, the company achieved a total revenue of about 5 billion yuan and a profit of 1.
-
2022 AD/PD International Conference: In-depth exploration of the role of gut microbiota in the pathogenesis and treatment of Parkinson's disease
Time of Update: 2022-04-17
Chen Shengdi, a professor of neurology at Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, shared the report "Non-drug therapy for neurodegenerative diseases" at the symposium, introducing the help of cognitive and Tai Chi training for patients with cognitive impairment, and may help alleviate inflammation .
-
When the epidemic comes, where are the scientific workers who asked for money first when they do things?
Time of Update: 2022-04-17
Which unit and which scientific and technological workers swore to say that their unit's ability, their own ability, or that their ability was not good, but after the state gave them funds to raise and strengthen them, they would make contributions when the country needs them .
-
He Jiankui released in 'gene-edited baby' case, sentenced to three years
Time of Update: 2022-04-17
The court heard and found that since 2016, He Jiankui, a former associate professor of Southern University of Science and Technology, learned that human embryo gene editing technology could obtain commercial benefits, that is, conspired with Zhang Renli, a medical institution in Guangdong Province, and Qin Jinzhou, a medical institution in Shenzhen, in knowingly violating the state.
-
No more than $75 million!
Time of Update: 2022-03-08
In addition to this cooperation, on January 20, Huadong Medicine also issued an announcement that the application for the Phase I clinical trial of DR30303 for injection, a new class 1 biological product declared by the holding subsidiary Doer Biotech, was approved, and the drug indication is Claudin18.
-
CSPC acquires Zhuhai Zhifan, increasing the number of biopharmaceuticals
Time of Update: 2022-03-08
The CSPC acquisition of Mingkang Bio will also obtain a new generation of thrombolytic new drug recombinant human TNK tissue plasminogen activator (trade name: Mingfule) .
-
The Internet medical industry has entered the peak season of development, and another giant cross-border layout!
Time of Update: 2022-03-07
It is worth mentioning that as early as July 2017, China Telecom joined hands with the domestic imaging giant Neusoft Medical to form a regionalized health care big data aggregation and service center in the entire northeastern region including Heiji and Liaoning provinces.
-
Another pharmaceutical company has completed hundreds of millions of financing, focusing on the research and development of original anti-tumor small molecule new drugs
Time of Update: 2022-03-07
According to relevant statistics, in January 2022, a total of 28 key pharmaceutical companies in the new drug field completed investments, with a total financing amount exceeding 5 billion yuan .
According to the data, Qinhao Pharmaceutical is a global innovative biopharmaceutical company, focusing on the development of original anti-tumor small molecule new drugs .
-
Yuandong Biological Announcement: It plans to invest 245 million yuan to participate in the big health industry fund
Time of Update: 2022-03-06
Yuandong Biology stated in the announcement that the company uses the industry experience, resource advantages and management platform of professional investment institutions to obtain corresponding industry resources and reserves of potential direct bidding; at the same time, it combines the management experience and risk control of fund managers and general partners.
-
In order to integrate the advantages of core products, the pharmaceutical company's business in China has undergone major adjustments
Time of Update: 2022-03-06
After the adjustment, AstraZeneca China's business structure will be divided into four segments, namely: Oncology Division; Respiratory, Digestive and Autoimmune Division; Cardiovascular, Renal and Metabolism Division; Rare Disease Division .
